Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

BARDA funds advanced development of drug to treat bone marrow injury associated with acute radiation syndrome

Date: September 15, 2011

Company: Neumedicines, Inc., Pasadena, Calif.

Contract amount: Approximately $17 million over 18 months and can be extended for a total of five years and up to $274 million

About the contract: Neumedicines will conduct studies to begin evaluating the safety and efficacy of a drug to treat bone marrow injuries from exposure to high levels of radiation, such as after a nuclear attack, and will develop manufacturing processes for the drug and manufacture small amounts of the drug for testing. The contract builds on work conducted under a BARDA contract issued in 2008. Under that contract, Neumedicines conducted studies indicating that the drug known as NMIL12-1 or HemaMax mitigates bone marrow damage caused by acute ionizing (damaging) radiation 24 hours after a person is exposed to radiation and that the drug promotes regeneration of multiple types of blood cells.

Additional information: BARDA is seeking additional proposals for products that potentially could treat or illness and injury from acute radiation syndrome, as well as improved diagnostic tools to measure the radiation dose a person has absorbed after a nuclear denotation or radiation accident. 

Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 at

Procurement Announcement:  Contract Award under BAA-BARDA-09-34

PHE Newsroom

Submit an Inquiry


Watch, Listen, Subscribe

Facebook Exit Icon Twitter Exit Icon YouTube Exit Icon
Email via GovDelivery Exit Icon LinkedIn Exit Icon

  • This page last reviewed: January 11, 2018